

Time and date	11.45 am – 12.00 noon Friday 19 June 2026
Venue	Lambton Ballroom InterContinental Wellington 2 Grey Street Wellington Central
Apologies	Karen Warman
Agenda	Item 1: Welcome, apologies and proxies
	Item 2: Adoption of minutes <ul style="list-style-type: none"> • Annual General Meeting held on 8 April 2025 • Special General Meeting held on 14 October 2025
	Item 3: 2025 performance report <ul style="list-style-type: none"> • Report of the Chair • 2025 financial statement
	Item 4: Interests declared by Officers
	Item 5: Motions for resolution <ul style="list-style-type: none"> • Resolution to defer the election of the Executive
	Item 6: General business
	Item 7: Acknowledgements and close

**Draft Minutes of the Annual General Meeting of the
Melanoma Network of New Zealand Incorporated (MelNet)
Online via Zoom
7.30 – 8.05 pm Tuesday 8 April 2025**

Members Present:

Gary Duncan (Meeting Chair), Chris Boberg, Cris Print, Jeat Lee, Amanda Oakley, Keith Monnington, Will Hunt, Sam Mayhew, Susan Seifried, Marion Peat, Victoria Francis, Abbie Cameron, Jody Jordan, Dan Butler, Richard Martin, Annie Wong, Richard Massey, Katrina Patterson (CEO and minute taker)

Apologies:

None

1. Welcome, apologies and proxies

Gary Duncan, Co-Chair of the Executive Committee, welcomed those present to the Annual General Meeting of MelNet. Introductions were made. There were no apologies or proxies.

2. Draft minutes of 11 May 2024 Annual General Meeting

The draft minutes of the 11 May 2024 meeting were approved. (Moved: Gary Duncan, seconded: Susan Seifried, Approved: All). There were no matters arising.

3. Report of the Executive Committee Co-Chairs

Gary Duncan, Meeting Chair, spoke to the circulated report of the Executive Committee Co-Chairs, with input from various members of the Executive Committee.

He acknowledged the contributions of Amanda Oakley, whose efforts in delivering early detection education on behalf of MelNet have been invaluable; Annie Wong and Jody Jordan for the expert clinical insights they have provided to Pharmac on funding of additional melanoma therapies; Susan Seifried for her dedication to maintaining the Quality Statements; and all others who have supported MelNet over the past year.

The report presented was approved (Moved: Gary Duncan, Seconded: Chris Boberg, Approved: All).

4. Statement of Accounts

The statement of accounts for the period 1 January to 31 December 2024 was presented.

The accounts presented were approved. (Moved: Gary Duncan, Seconded: Jody Jordan, Approved: All).

5. Conflicts of Interest Register

A register documenting conflicts of interest declared by MelNet Officers was presented.

6. Resolution to rebrand to Skin Cancer New Zealand

The Meeting Chair spoke to the circulated resolution to rebrand MelNet to Skin Cancer New Zealand. Susan Seifried and Cris Print expressed their support for this move.

The resolution was accepted (Moved: Gary Duncan, Seconded: Susan Seifried, Approved: All)

7. Resolution that the election of the Executive Committee be deferred

The Meeting Chair spoke to the circulated resolution to defer the election of the Executive Committee until later in the year, following a review of the Constitution.

Richard Martin commented that he felt the Committee was too large, and other governance structures should be considered, such as clinical advisory groups.

The resolution was accepted (Moved: Gary Duncan, Seconded: Chris Boberg, Approved: All)

8. General business

Will Hunt spoke to his research on wide local excision practices among dermatologists worldwide. Those in attendance suggested it would be worthwhile to extend this research to surgeons and GPs with advanced skill sets.

9. Acknowledgements and Closing

The Meeting Chair thanked Marion Peat and Katrina Patterson for their efforts over the past year, and the Executive Committee who generously contributed their time and expertise.

Katrina Patterson thanked the members of MelNet for their ongoing support, and Chris Boberg and Gary Duncan for their ongoing leadership.

The meeting closed at 8.05 pm.

DRAFT

**Draft Minutes of a Special General Meeting of the
Melanoma Network of New Zealand Incorporated (MelNet)
Online via Microsoft Teams
7.30 – 7.55 pm Tuesday 14 October 2025**

Members Present:

Chris Boberg (Meeting Chair), Gary Duncan, Abbie Cameron, Keith Monnington, Alistair Brown, Marion Peat, Amanda Oakley, Geraldine Wilson, Richard Massey, Jody Jordan, Victoria Beedle, Daniel Butler, Bronwen McNoe, Jeat Lee, Sam Mayhew, Susan Seifried, Marc Lawrence, Katrina Patterson (CEO and minute taker)

Apologies:

Cris Print, Annie Wong, Victoria Francis

Proxies:

Katrina Patterson for Cris Print, Annie Wong and Victoria Francis

1. Welcome, apologies and proxies

Chris Boberg, Co-Chair of the Executive Committee, welcomed those present to this Special General Meeting of MelNet. Apologies and proxies were noted. A quorum was confirmed.

2. Adoption of Skin Cancer New Zealand Constitution

Members considered and voted on the proposed new Constitution for Skin Cancer New Zealand Incorporated.

Resolution: That the Constitution as circulated be adopted.

Moved: Chris Boberg

Seconded: Keith Monnington

Approved: All

Outcome: Carried unanimously.

3. Announcement of elected Executive members

Attendees were advised that as only six nominations were received, all nominees would be appointed unopposed.

The following individuals were confirmed as members of the inaugural Executive of Skin Cancer New Zealand Incorporated:

- Abbie Cameron, Nurse, Christchurch
- Alistair Brown, Dermatologist, Tauranga
- Dan Butler, Plastic Surgeon, Tauranga
- Gary Duncan, Plastic Surgeon, Hawke's Bay
- Sam Mayhew, Skin Cancer Doctor, Auckland
- Susan Seifried, General Surgeon, Nelson

4. Acknowledgements and Closing

Sincere thanks were extended to outgoing committee members who have contributed to the organisation's work over the years.

Gary Duncan and Susan Seifried expressed special appreciation to Chris Boberg for his hard work, dedication and leadership in guiding the organisation from its inception to this important milestone.

The meeting closed at 7.55 pm.

DRAFT



2025

Performance Report

Snapshot

Skin cancer in NZ

Skin cancer is New Zealand's most common cancer, accounting for around 80% of all new cancer diagnoses.

Approximately 100,000 people are diagnosed annually.

New Zealand has one of the highest melanoma mortality rates globally.

Around 500 Kiwis lose their lives to skin cancer each year — nearly twice the road toll.

Skin cancer costs the health system an estimated \$450+ million per year.

Up to 90% of skin cancers are preventable and if caught early, nearly all are curable.



Reduce
skin cancer.



Improve
outcomes.

Save
lives.



Our mission

To lead a cohesive national approach to reduce the number of people who develop skin cancer, and ensure those affected receive early diagnosis and quality best-practice care.

Our objectives



Lead & advocate

Drive meaningful improvements in skin cancer prevention, detection, treatment and research.



Connect & educate

Upskill our health workforce, strengthen partnerships among skin cancer professionals and engage communities.



Thrive & communicate

Expand our reach, deepen our impact and strengthen who we are to create lasting change.

Contents

Chairs report	1
Acknowledgements	3
Our year in review	4
Skin lesion and dermoscopy course	5
Skin cancer study day for nurses	6
Nurses special interest group	7
Skin Cancer Prevention and Early Detection Strategy	8
Online education programme	9
Improved access to melanoma medicines	10
Rebrand	11
Financial performance	12
Our membership	16
Our team	17
Contact information	17

Chair's report

2025 – a year of transition

2025 marked the start of our transformation from MelNet to Skin Cancer NZ. This change reflects a deliberate shift to better align our name with our purpose and the impact we are striving to make nationally.

While our name and look are changing, our commitment to preventing skin cancers, supporting early detection, and improving outcomes for all New Zealanders affected by skin cancer remains the same.

Our transition to Skin Cancer NZ has also marked a significant change in leadership. In October, we farewelled the MelNet Executive Committee, many of whom had dedicated years of service to building the organisation into what it is today. At the same time we welcomed the inaugural Executive for Skin Cancer New Zealand to guide the next phase of growth and impact. It has been an honour to step into the role of Chair during this time, and I look forward to working alongside the incoming Executive to strengthen our impact, sustainability, and voice within the health system.

Key achievements and impact

We are proud of the continued impact we have had this year.

A major milestone was our advocacy for improved access to effective melanoma treatments in New Zealand. Our clinical experts played an important role in shaping Pharmac's proposal to fund additional treatment options, which came into effect on 1 June 2025.



This represents an important step forward for people living with advanced melanoma and brings New Zealand closer to international standards of care.

We also made important progress in strengthening the national approach to skin cancer prevention and early detection through the launch of the *Skin Cancer Prevention and Early Detection Strategy*. This document provides a clear roadmap for prevention and early detection interventions and is already helping to align efforts across health, education, workplace, sport and recreation sectors. It's also provided us and others in the sector opportunities to engage with Ministers and other stakeholders to highlight the growing burden of skin cancer, the need for greater investment, and the importance of a more coordinated approach to prevention and early detection.

Education remains a core part of our work. Over the year, we delivered a range of national education activities that support clinical practice and workforce development. These are helping to strengthen consistent, evidence-based practice and build capability across the country.

Looking ahead to 2026

Our priorities will focus on:

- Strategic planning for our next phase of growth.
- Building sustainable funding to support an expanding programme of work.
- Strengthening and extending our reach and impact across New Zealand.
- Continuing to build a strong, connected national voice for skin cancer prevention, early detection and care.

Acknowledgements

We would like to express our thanks to all those who have contributed to our work this year.

Our operational team whose efforts continue to strengthen our impact.

The outgoing Executive for their dedication and service over many years, and the incoming Executive for the leadership and strategic direction they will bring.

Those who have given their time and expertise to support our initiatives – your input is central to the quality, credibility, and impact of our work.

Our partners, donors, sponsors, and members - your support is the foundation on which our work rests. Without you, none of our achievements would be possible.

We look forward to continuing this important work together in 2026 and beyond.



Thank you

We are incredibly grateful to all those who have supported our work over the past year.

Project funding and strategic initiatives

Te Whatu Ora - Health New Zealand

Grant providers

Aotearoa Gaming Trust

Education and professional events

MSD, Skin Cancer Symposiums, Novartis, event registrants

Website donors

Cancer Society of New Zealand, Skin Institute, Skin Cancer Symposiums Amanda, Andrew and Veronica, Antonio, Brian, Calum Stannett, Chris Boberg, Daniel, Espy Skin, Fiona, Geraldine Wilson, Hamilton Skin Cancer Centre, Harvey, Jenny, Kesmed, Mark, Molecheck, Mole Doctors, Natalie, Nicola, Patricia, Paul and Karyn, Skin Aware, Skinspect, SKiNTUITION

General donors

Molecheck

In kind support

Skin Cancer College of Australasia

We also acknowledge our partners who made an early commitment to support the 2026 NZ Skin Cancer Summit

New Zealand Skin Cancer Doctors Society, Melanoma and Skin Cancer Trials, Skin Cancer Symposiums, Skin Cancer College of Australasia, Bernier Pharmaceuticals, Novartis, Skin Doctor Shop

Our year in review

Educate and connect

- Delivered a programme of education activities, including:
 - 1 Skin Lesion and Dermoscopy course (Auckland, 39 attendees)
 - 1 Skin Cancer Study Day for Nurses (Auckland, 91 attendees)
 - 1 webinar: Perioperative Therapies (Online, 177 attendees)
 - 1 Melanoma Research and Therapy Special Interest Group meeting (Dunedin, 25 attendees)
 - 2 Nurses in Skin Cancer Special Interest Group meetings (virtual, 13 and 27 attendees)
- Nurses in Skin Cancer Special Interest Group grew to 64 members (22 new). The group also maintained an active WhatsApp community supporting ongoing peer connection and communication.
- Planning for the NZ Skin Cancer Summit (June 2026, Wellington).
- 120 research articles were shared via the website, supporting ongoing access to current evidence and learning.

Lead and advocate

- Launched the *2024 - 2028 Skin Cancer Prevention and Early Detection Strategy* (the Strategy) in February 2025.
- Ongoing advocacy to support the Strategy, including engagement with Ministers, Health New Zealand, the Cancer Control Agency, and local councils.
- Presented and engaged at key sector events to support and socialise the Strategy, including the Skin Cancer College of Australasia Congress and Parliamentary event and NZ Skin Cancer Doctors Society conference.
- Developed a business case for an online education programme for primary and allied health professionals.
- Continued engagement with Pharmac regarding proposals for funding melanoma medicines and their implementation. .
- Advocacy for development and expansion of the CanShare platform.
- Reinstated Working Group and commenced review of NZ Melanoma Clinical Guidelines.

Thrive and communicate

- Commenced the rebrand to Skin Cancer NZ, including updating the Constitution and legal name change.
- Distributed monthly e-newsletters to members (16,517 sent).
- Appointed a new Executive Board.
- Developed a replacement MelNet website.



Skin lesion and dermoscopy course

March 2025, Auckland

In conjunction with Goodfellow Symposium

Presented by Dr Chris Boberg and Dr Andrew MacGill, this one-day course introduced participants to the clinical and dermatoscopic assessment of common benign and malignant skin lesions, with a particular focus on pigmented lesions..

The course was designed to build practical confidence in identifying and assessing skin lesions in everyday clinical practice, supporting better decision-making and helping to reduce unnecessary excisions of benign lesions.

Attended by 39 participants, the course received overwhelmingly positive feedback. Post-course evaluation showed that all respondents felt more confident using a dermatoscope and more confident in their knowledge of skin lesions following the course.

“Great session, thanks. I’ll start using my new knowledge on Monday.”

Skin cancer study day for nurses

November 2025, Auckland

This one-day course, targeted at nurses, aimed to increase understanding of best practice in skin cancer prevention, early detection, treatment and care, the journey of a skin cancer patient, and the critical role nurses play throughout that journey.

A total of 95 nurses registered for the event. Feedback was overwhelmingly positive, with 98% of respondents reporting an improved understanding of skin cancer and 93% indicating an interest in pursuing further skin cancer education opportunities.

“A very well put together day. I learnt so much - it was well worth the investment and it will definitely change my practice.”





Nurses Special Interest Group

This group continued to grow in 2025, reaching 64 members by the end of the year. The group provides an important forum for nurses working in skin cancer to connect, share experiences, support one another, and continue developing their knowledge and skills.

Two virtual meetings were held. The first focused on the New Zealand Melanoma Clinical Guidelines and was presented by Dr Susan Seifried, while the second explored skin cancer prevention efforts in New Zealand and was presented by Dr Bronwen McNoe. Both sessions sparked valuable discussion and engagement among members.

Significant progress was made on the development of a professional pathway and competency framework for nurses working in skin cancer, helping to support clearer professional development opportunities and recognition within the sector.

The group's WhatsApp community continued to flourish as a space for peer support, networking, resource sharing, and clinical discussion between meetings.

“This group has been a fantastic way of keeping nurses connected. I really appreciate all the encouragement, guidance and opportunities for growth it provides.”

Skin Cancer Prevention and Early Detection Strategy


A major milestone for the year was the launch of the 2024–2028 New Zealand Skin Cancer Prevention and Early Detection Strategy in February.

Led by Skin Cancer NZ, the Strategy was developed by a multidisciplinary working group of experts, informed by broad sector input and supported by Health New Zealand. It provides a clear national roadmap for reducing the impact of skin cancer in New Zealand.

The Strategy was disseminated widely across sectors involved in skin cancer prevention and early detection, including health, education, sports, recreation, and workplaces.

It's release generated significant momentum for advocacy throughout the year. It was presented and discussed with Ministers and Government agencies, and featured prominently at sector events including the Skin Cancer College of Australasia Congress and Parliamentary Event, and the NZ Skin Cancer Doctors Society Conference.

Importantly, the Strategy also helped strengthen collaboration and sector alignment by providing a shared direction, and creating new opportunities for organisations to connect, align priorities, and work more cohesively across the sector.





Online education programme

This year, with support from Health New Zealand, a business case was developed for an online education programme for health professionals, and development of the programme commenced.

Aligned with Recommendation 2 of the *Skin Cancer Prevention and Early Detection Strategy*, the programme will strengthen knowledge and confidence in skin cancer prevention, earlier recognition of suspicious lesions, and more consistent, evidence-based practice across New Zealand.

It is primarily aimed at primary care practitioners, particularly general practitioners, while also providing content relevant to allied health professionals and others who may encounter skin cancer in their day-to-day work.

Delivered as a 10-module, self-paced online course, the programme will incorporate case-based learning, practical skill development, interactive activities, and assessments. Topics range from sun protection through to the recognition and management of common skin cancers, as well as foundational dermoscopy and biopsy techniques.

The programme is currently in development and is anticipated to be freely available on Health New Zealand's learning management system by October 2026.

Improved access to melanoma medicines

One of our most significant achievements this year was the successful outcome of ongoing advocacy to improve access to melanoma medicines in New Zealand.

In May, Pharmac announced the widening of access to existing treatments and the funding of new medicines for people with stage IIIB to stage IV melanoma. Pharmac also confirmed expanded access to treatments to support the management of immune checkpoint inhibitor-related toxicity.

Skin Cancer NZ played an important role in this process. Our oncology representatives worked alongside Pharmac to inform the development of its proposal, providing expert advice to help ensure it was clinically appropriate and aligned with evolving international standards of care. Our Melanoma Research and Therapy Special Interest Group also provided an important platform that helped initiate and progress discussions with Pharmac on the need for improved access to medicines to manage immune checkpoint inhibitor-related toxicity.

We are proud of the contribution made by our organisation in supporting this outcome. This decision represents a major step forward for patients and clinicians and reflects sustained sector advocacy over a number of years.





Rebrand

At the Annual General Meeting in April, members passed a resolution to rebrand the organisation to Skin Cancer NZ.

This change ensures our brand accurately reflects the breadth of our work across all forms of skin cancer, not just melanoma. It also creates an opportunity to strengthen our national visibility.

The organisation's name has since been legally changed to Skin Cancer New Zealand, and an updated Constitution was adopted at a Special General Meeting in October 2025. A new Executive Board was also elected at this meeting. Following this, the Executive undertook a recruitment process to appoint three additional members from outside the membership. This brought expertise in marketing, finance, and fundraising to strengthen organisational capability and support long-term sustainability.

The transition to the new identity will be implemented over the next 12 months as we progressively update our communications, systems, and other materials.

We thank our members for their continued support and engagement as we move forward with this important transition.

Financial performance

Statement of Receipts and Payments

For the year ended 31 December 2025

	Current Year	Last Year
Opening balance in bank account(s) and cash on hand:*	154,180	108,874
Plus cash received from operating activities		
Donations, koha, bequests, and other fundraising:*	12,572	4,324
General grants received:*	25,000	25,000
Service delivery grants/contracts:*	90,000	75,000
Membership fees and subscriptions:*	0	0
Sale of goods & services (commercial activities):*	41,624	89,367
Interest or dividends received:*	0	0
Other cash received:*	2,180	943
Total cash received from operating activities:	171,376	194,634
Less cash paid for operating activities		
Fundraising costs:*	0	0
Employee remuneration and other employee related costs:*	102,881	99,187
Volunteer related costs:*	0	0
Costs related to sale of goods or services (commercial activities):*	26,810	34,523
Other costs related to delivery of entity objectives:*	57,474	12,159
Grants and donations paid:*	0	0
Other cash paid:*	0	0
Total cash paid for operating activities:	187,165	145,869
GST (paid) or refunded in the financial year:*	-3,016	-3,459
Operating Surplus/Deficit		
Cash surplus or (deficit) from operating activities:	-18,805	45,306

<u>Plus cash received from other activities</u>	Current Year	Last Year
Sale of investments:*	0	0
Sale of other assets:*	0	0
Cash received from loans and borrowings:*	0	0
Total cash received from other activities:	0	0
<u>Less cash paid for other activities</u>		
Purchase of investments:*	0	0
Purchase of other assets:*	0	0
Repayments of loans and borrowings:*	0	0
Total cash paid for other activities:	0	0
Cash surplus or (deficit) from other activities:	0	0
Income tax (paid) or refunded (if applicable):*	0	0
Increase or (decrease) in cash for the year:	-18,805	45,306
Closing balance in bank account(s) and any cash on hand:	135,375	154,180
Represented By:		
Closing balance of bank account(s):*	135,375	154,180
Balance invested in term deposit(s):*	0	0
Cash on hand:*	0	0
Total cash balances held:	135,375	154,180

Notes

- 1.This report has been prepared in accordance with XRB's Tier 4 (NFP) Standard. Skin Cancer NZ is permitted by law to apply this standard. All transactions included in the Statement of Receipts and Payments have been reported on a cash basis.
- 2.Skin Cancer NZ is registered for Goods and Services Tax (GST). All amounts recorded in the Performance Report are exclusive of GST (if any).

Significant Assets or Liabilities

Skin Cancer NZ does not have any significant assets or liabilities in the current or previous financial year.

Related Party Transactions

Skin Cancer NZ did not have any related party transactions in the current or previous financial year.

Correction of Errors

The wrong closing balanced was entered in the previous year (\$154,237). This has been corrected in this report (\$154,180).

Approval of financial report

This report has been approved by the Skin Cancer NZ Executive.



Become a Founding Member of Skin Cancer NZ

Help fight skin cancer and save lives



2 in 3

New Zealanders will be diagnosed with skin cancer in their lifetime.

Skin cancer is New Zealand's most common cancer - and it can affect anyone. Yet up to 90% of skin cancers are preventable, and almost all are curable when caught early.

This is where you can make a difference.

As a Founding Member, you'll help shape skin cancer prevention, improve early detection, and support better care across New Zealand.

Only 100 places available


Be part of Skin Cancer NZ from the beginning and help shape the future of skin cancer care in New Zealand.


Scan to join




Join and help today

As a Founding Member, you will:

 Support national prevention and, early detection initiatives, and life-saving education.

 Strengthen access and improve the quality of skin cancer care.

 Make a lasting impact and be recognised for your support.



New Zealand's specialist skin cancer charity



hello@skincancer.org.nz



skincancer.org.nz

Our membership



1551
members in total




120
new members
in 2025

Membership by occupation

- Dermatologist
- Allied Health
- GP
- Surgeon
- Health promoter
- Nurse
- Oncologist
- Other
- Pathologist
- Researcher



Membership by location



Our membership spans a wide range of professions from across New Zealand.

Our team

Skin Cancer NZ Executive

Susan Seifried (Chair)
Sam Mayhew (Deputy Chair)
Abbie Cameron
Alistair Brown
Dan Butler
Gary Duncan
Julie Moon
Karen Warman
Renata Krzyszycha

Outgoing MelNet Executive

Chris Boberg (Co-Chair)
Amanda Oakley
Annie Wong
Bronwen McNoe
Cris Print
Jeat Lee
Jody Jordan
Keith Monnington
Richard Martin
Richard Massey
Victoria Francis

Operations team

Katrina Patterson
Marion Peat

Contact information



www.skincancer.org.nz



hello@skincancer.org.nz



027 492 6650



[Skin Cancer New Zealand](#)



[@ Skin Cancer New Zealand](#)

As of 5 May 2026

Name	Role	Interests
Dr Susan Seifried	Executive Chair	<ul style="list-style-type: none"> Employee Health NZ Nelson Marlborough Chair Melanoma Clinical Guidelines Working Group Under consideration to be member of the Melanoma and Skin Cancer Trials Board of Directors
Dr Sam Mayhew	Executive Deputy Chair	<ul style="list-style-type: none"> Skin Cancer Doctor & Surgical Provider - Molemap The Dermatology Group - GPSI Provider Member NZSCD La Roche Posay Advisory Groups: Dermocosmetics, seborrhoeic Dermatitis. La Roche Posay educational webinar presenter
Abbie Cameron	Executive member	<ul style="list-style-type: none"> Employee Melanoma NZ Skin Cancer Collective Director Affiliate member NZSCD
Dr Alistair Brown	Executive member	None
Mr Dan Butler	Executive member	<ul style="list-style-type: none"> Co-director Butler Plastic Surgery Ltd Co-director Da Vinci Clinic, Tauranga Employee Health NZ Bay of Plenty
Mr Gary Duncan	Executive member	None
Karen Warman	Executive member	None
Julie Moon	Executive member	<ul style="list-style-type: none"> Employee of Alto Packaging Ltd - a division of Pact Group
Renata Krzyszycha	Executive member	<ul style="list-style-type: none"> Business Development Manager, Great Potentials Professional Member of Fundraising Institute of Australia
Katrina Patterson	Chief Executive	None

Resolution to defer election of the Executive Board

For consideration at the 2026 AGM

Background

At the Special General Meeting held in October 2025, members appointed a new Executive following the adoption of the Constitution for Skin Cancer New Zealand Incorporated.

Under the Constitution, this inaugural Executive was appointed on a staggered term basis, with half of the members serving a one-year term and half serving a two-year term, to ensure continuity and rotation of governance.

Typically, the next election of the Executive would be held at the 2026 Annual General Meeting. Due to the timing of the October 2025 appointment, this would result in a shortened initial term of approximately eight months for part of the Executive.

The organisation is currently in a significant period of transition, where key governance and operational structures, organisational brand and long-term strategic direction are still being established and embedded.

The Executive considers continuity of leadership important during this time to ensure stability, consistency of decision-making, and effective implementation of the new Constitution and organisational direction.

Proposal

The Executive proposes that the election due for the 2026 Annual General Meeting be deferred until the 2027 Annual General Meeting.

This would enable the current Executive to complete a full term following their appointment in October 2025 and provide continuity of governance during a significant period of organisational transition and development.

If approved, the current Executive will remain in office until the 2027 Annual General Meeting, at which time elections will be held in accordance with the Constitution.